 | • レポートコード：QYR2104Z2015 • 出版社/出版日：QYResearch / 2021年4月10日 ※2024年版があります。お問い合わせください。 • レポート形態：英文、PDF、96ページ • 納品方法：Eメール（納期：3日） • 産業分類：医療 |
| Single User | ￥577,200 (USD3,900) | ▷ お問い合わせ |
| Multi User/Five User | ￥865,800 (USD5,850) | ▷ お問い合わせ |
| Enterprise License（同一法人内共有可） | ￥1,154,400 (USD7,800) | ▷ お問い合わせ |
• お支払方法：銀行振込（納品後、ご請求書送付）
レポート概要
| QYResearch社発行の本調査資料では、デュシェンヌ型筋ジストロフィー治療のグローバル市場（2016年～2027年）について調べ、市場動向、主要企業の市場シェア、種類別市場規模（疼痛管理薬、コルチコステロイド、プレドニゾロン、プレドニゾン、デフラザコート）、用途別市場規模（病院、診療所、在宅ケアの設定）、主要地域別市場規模（北米、アメリカ、ヨーロッパ、アジア、日本、中国、韓国、インド、東南アジア、中南米、中東、アフリカ等）、関連企業情報などを掲載しています。 ・市場概要 ・デュシェンヌ型筋ジストロフィー治療の市場動向 ・企業の競争状況、市場シェア ・デュシェンヌ型筋ジストロフィー治療の種類別市場規模（疼痛管理薬、コルチコステロイド、プレドニゾロン、プレドニゾン、デフラザコート） ・デュシェンヌ型筋ジストロフィー治療の用途別市場規模（病院、診療所、在宅ケアの設定） ・デュシェンヌ型筋ジストロフィー治療の北米市場規模2016-2027（アメリカ、カナダ） ・デュシェンヌ型筋ジストロフィー治療のヨーロッパ市場規模2016-2027（ドイツ、フランス、イギリス等） ・デュシェンヌ型筋ジストロフィー治療のアジア市場規模2016-2027（日本、中国、韓国、インド、東南アジア等） ・デュシェンヌ型筋ジストロフィー治療の中南米市場規模2016-2027（メキシコ、ブラジル） ・デュシェンヌ型筋ジストロフィー治療の中東・アフリカ市場規模2016-2027（トルコ、サウジアラビア等） ・主要企業情報（Bristol-Myers Squibb、FibroGen (US)、Italfarmaco (Italy)、Marathon、NS Pharma (US)、PTC Therapeutics (US)、Pfizer、ReveraGen BioPharma (US)、Santhera Pharmaceuticals (Switzerland)、Sarepta Therapeutics (US)） ・結論 |
Duchenne muscular dystrophy (DMD) therapeutics helps treat genetic disorder caused due to absence of dystrophin, a protein in the body. The symptoms of the disease include weakness in the muscles of the hips, pelvic area, thighs, and shoulders, and later in the muscles of arms, legs, and trunk.
Factors such as, increase in incidences of Duchenne muscular dystrophy and introduction of specific guidance for development for Duchenne muscular dystrophy drugs by FDA drive the market growth. However, fast track approval of these drugs by FDA and untapped growth opportunities in the emerging economies of Asia-Pacific and LAMEA are expected to fuel the market growth during the forecast period.
Market Analysis and Insights: Global Duchenne Muscular Dystrophy Therapeutics Market
The global Duchenne Muscular Dystrophy Therapeutics market size is projected to reach US$ 5792.4 million by 2026, from US$ 961.9 million in 2019, at a CAGR of 28.9% during 2021-2026.
With industry-standard accuracy in analysis and high data integrity, the report makes a brilliant attempt to unveil key opportunities available in the global Duchenne Muscular Dystrophy Therapeutics market to help players in achieving a strong market position. Buyers of the report can access verified and reliable market forecasts, including those for the overall size of the global Duchenne Muscular Dystrophy Therapeutics market in terms of revenue.
On the whole, the report proves to be an effective tool that players can use to gain a competitive edge over their competitors and ensure lasting success in the global Duchenne Muscular Dystrophy Therapeutics market. All of the findings, data, and information provided in the report are validated and revalidated with the help of trustworthy sources. The analysts who have authored the report took a unique and industry-best research and analysis approach for an in-depth study of the global Duchenne Muscular Dystrophy Therapeutics market.
Global Duchenne Muscular Dystrophy Therapeutics Scope and Market Size
Duchenne Muscular Dystrophy Therapeutics market is segmented by company, region (country), by Type, and by Application. Players, stakeholders, and other participants in the global Duchenne Muscular Dystrophy Therapeutics market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on revenue and forecast by Type and by Application in terms of revenue and forecast for the period 2016-2027.
Segment by Type
Pain Management Drugs
Corticosteroids
Prednisolone
Prednisone
Deflazacort
Segment by Application
Hospitals
Clinics
Home Care Settings
By Region
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Nordic
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
By Company
Bristol-Myers Squibb
FibroGen (US)
Italfarmaco (Italy)
Marathon
NS Pharma (US)
PTC Therapeutics (US)
Pfizer
ReveraGen BioPharma (US)
Santhera Pharmaceuticals (Switzerland)
1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Duchenne Muscular Dystrophy Therapeutics Market Size Growth Rate by Type: 2016 VS 2021 VS 2027
1.2.2 Pain Management Drugs
1.2.3 Corticosteroids
1.2.4 Prednisolone
1.2.5 Prednisone
1.2.6 Deflazacort
1.3 Market by Application
1.3.1 Global Duchenne Muscular Dystrophy Therapeutics Market Share by Application: 2016 VS 2021 VS 2027
1.3.2 Hospitals
1.3.3 Clinics
1.3.4 Home Care Settings
1.4 Study Objectives
1.5 Years Considered
2 Global Growth Trends
2.1 Global Duchenne Muscular Dystrophy Therapeutics Market Perspective (2016-2027)
2.2 Duchenne Muscular Dystrophy Therapeutics Growth Trends by Regions
2.2.1 Duchenne Muscular Dystrophy Therapeutics Market Size by Regions: 2016 VS 2021 VS 2027
2.2.2 Duchenne Muscular Dystrophy Therapeutics Historic Market Share by Regions (2016-2021)
2.2.3 Duchenne Muscular Dystrophy Therapeutics Forecasted Market Size by Regions (2022-2027)
2.3 Duchenne Muscular Dystrophy Therapeutics Industry Dynamic
2.3.1 Duchenne Muscular Dystrophy Therapeutics Market Trends
2.3.2 Duchenne Muscular Dystrophy Therapeutics Market Drivers
2.3.3 Duchenne Muscular Dystrophy Therapeutics Market Challenges
2.3.4 Duchenne Muscular Dystrophy Therapeutics Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Duchenne Muscular Dystrophy Therapeutics Players by Revenue
3.1.1 Global Top Duchenne Muscular Dystrophy Therapeutics Players by Revenue (2016-2021)
3.1.2 Global Duchenne Muscular Dystrophy Therapeutics Revenue Market Share by Players (2016-2021)
3.2 Global Duchenne Muscular Dystrophy Therapeutics Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
3.3 Players Covered: Ranking by Duchenne Muscular Dystrophy Therapeutics Revenue
3.4 Global Duchenne Muscular Dystrophy Therapeutics Market Concentration Ratio
3.4.1 Global Duchenne Muscular Dystrophy Therapeutics Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Duchenne Muscular Dystrophy Therapeutics Revenue in 2020
3.5 Duchenne Muscular Dystrophy Therapeutics Key Players Head office and Area Served
3.6 Key Players Duchenne Muscular Dystrophy Therapeutics Product Solution and Service
3.7 Date of Enter into Duchenne Muscular Dystrophy Therapeutics Market
3.8 Mergers & Acquisitions, Expansion Plans
4 Duchenne Muscular Dystrophy Therapeutics Breakdown Data by Type
4.1 Global Duchenne Muscular Dystrophy Therapeutics Historic Market Size by Type (2016-2021)
4.2 Global Duchenne Muscular Dystrophy Therapeutics Forecasted Market Size by Type (2022-2027)
5 Duchenne Muscular Dystrophy Therapeutics Breakdown Data by Application
5.1 Global Duchenne Muscular Dystrophy Therapeutics Historic Market Size by Application (2016-2021)
5.2 Global Duchenne Muscular Dystrophy Therapeutics Forecasted Market Size by Application (2022-2027)
6 North America
6.1 North America Duchenne Muscular Dystrophy Therapeutics Market Size (2016-2027)
6.2 North America Duchenne Muscular Dystrophy Therapeutics Market Size by Type
6.2.1 North America Duchenne Muscular Dystrophy Therapeutics Market Size by Type (2016-2021)
6.2.2 North America Duchenne Muscular Dystrophy Therapeutics Market Size by Type (2022-2027)
6.2.3 North America Duchenne Muscular Dystrophy Therapeutics Market Size by Type (2016-2027)
6.3 North America Duchenne Muscular Dystrophy Therapeutics Market Size by Application
6.3.1 North America Duchenne Muscular Dystrophy Therapeutics Market Size by Application (2016-2021)
6.3.2 North America Duchenne Muscular Dystrophy Therapeutics Market Size by Application (2022-2027)
6.3.3 North America Duchenne Muscular Dystrophy Therapeutics Market Size by Application (2016-2027)
6.4 North America Duchenne Muscular Dystrophy Therapeutics Market Size by Country
6.4.1 North America Duchenne Muscular Dystrophy Therapeutics Market Size by Country (2016-2021)
6.4.2 North America Duchenne Muscular Dystrophy Therapeutics Market Size by Country (2022-2027)
6.4.3 United States
6.4.3 Canada
7 Europe
7.1 Europe Duchenne Muscular Dystrophy Therapeutics Market Size (2016-2027)
7.2 Europe Duchenne Muscular Dystrophy Therapeutics Market Size by Type
7.2.1 Europe Duchenne Muscular Dystrophy Therapeutics Market Size by Type (2016-2021)
7.2.2 Europe Duchenne Muscular Dystrophy Therapeutics Market Size by Type (2022-2027)
7.2.3 Europe Duchenne Muscular Dystrophy Therapeutics Market Size by Type (2016-2027)
7.3 Europe Duchenne Muscular Dystrophy Therapeutics Market Size by Application
7.3.1 Europe Duchenne Muscular Dystrophy Therapeutics Market Size by Application (2016-2021)
7.3.2 Europe Duchenne Muscular Dystrophy Therapeutics Market Size by Application (2022-2027)
7.3.3 Europe Duchenne Muscular Dystrophy Therapeutics Market Size by Application (2016-2027)
7.4 Europe Duchenne Muscular Dystrophy Therapeutics Market Size by Country
7.4.1 Europe Duchenne Muscular Dystrophy Therapeutics Market Size by Country (2016-2021)
7.4.2 Europe Duchenne Muscular Dystrophy Therapeutics Market Size by Country (2022-2027)
7.4.3 Germany
7.4.4 France
7.4.5 U.K.
7.4.6 Italy
7.4.7 Russia
7.4.8 Nordic
8 Asia-Pacific
8.1 Asia-Pacific Duchenne Muscular Dystrophy Therapeutics Market Size (2016-2027)
8.2 Asia-Pacific Duchenne Muscular Dystrophy Therapeutics Market Size by Type
8.2.1 Asia-Pacific Duchenne Muscular Dystrophy Therapeutics Market Size by Type (2016-2021)
8.2.2 Asia-Pacific Duchenne Muscular Dystrophy Therapeutics Market Size by Type (2022-2027)
8.2.3 Asia-Pacific Duchenne Muscular Dystrophy Therapeutics Market Size by Type (2016-2027)
8.3 Asia-Pacific Duchenne Muscular Dystrophy Therapeutics Market Size by Application
8.3.1 Asia-Pacific Duchenne Muscular Dystrophy Therapeutics Market Size by Application (2016-2021)
8.3.2 Asia-Pacific Duchenne Muscular Dystrophy Therapeutics Market Size by Application (2022-2027)
8.3.3 Asia-Pacific Duchenne Muscular Dystrophy Therapeutics Market Size by Application (2016-2027)
8.4 Asia-Pacific Duchenne Muscular Dystrophy Therapeutics Market Size by Region
8.4.1 Asia-Pacific Duchenne Muscular Dystrophy Therapeutics Market Size by Region (2016-2021)
8.4.2 Asia-Pacific Duchenne Muscular Dystrophy Therapeutics Market Size by Region (2022-2027)
8.4.3 China
8.4.4 Japan
8.4.5 South Korea
8.4.6 Southeast Asia
8.4.7 India
8.4.8 Australia
9 Latin America
9.1 Latin America Duchenne Muscular Dystrophy Therapeutics Market Size (2016-2027)
9.2 Latin America Duchenne Muscular Dystrophy Therapeutics Market Size by Type
9.2.1 Latin America Duchenne Muscular Dystrophy Therapeutics Market Size by Type (2016-2021)
9.2.2 Latin America Duchenne Muscular Dystrophy Therapeutics Market Size by Type (2022-2027)
9.2.3 Latin America Duchenne Muscular Dystrophy Therapeutics Market Size by Type (2016-2027)
9.3 Latin America Duchenne Muscular Dystrophy Therapeutics Market Size by Application
9.3.1 Latin America Duchenne Muscular Dystrophy Therapeutics Market Size by Application (2016-2021)
9.3.2 Latin America Duchenne Muscular Dystrophy Therapeutics Market Size by Application (2022-2027)
9.3.3 Latin America Duchenne Muscular Dystrophy Therapeutics Market Size by Application (2016-2027)
9.4 Latin America Duchenne Muscular Dystrophy Therapeutics Market Size by Country
9.4.1 Latin America Duchenne Muscular Dystrophy Therapeutics Market Size by Country (2016-2021)
9.4.2 Latin America Duchenne Muscular Dystrophy Therapeutics Market Size by Country (2022-2027)
9.4.3 Mexico
9.4.4 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Duchenne Muscular Dystrophy Therapeutics Market Size (2016-2027)
10.2 Middle East & Africa Duchenne Muscular Dystrophy Therapeutics Market Size by Type
10.2.1 Middle East & Africa Duchenne Muscular Dystrophy Therapeutics Market Size by Type (2016-2021)
10.2.2 Middle East & Africa Duchenne Muscular Dystrophy Therapeutics Market Size by Type (2022-2027)
10.2.3 Middle East & Africa Duchenne Muscular Dystrophy Therapeutics Market Size by Type (2016-2027)
10.3 Middle East & Africa Duchenne Muscular Dystrophy Therapeutics Market Size by Application
10.3.1 Middle East & Africa Duchenne Muscular Dystrophy Therapeutics Market Size by Application (2016-2021)
10.3.2 Middle East & Africa Duchenne Muscular Dystrophy Therapeutics Market Size by Application (2022-2027)
10.3.3 Middle East & Africa Duchenne Muscular Dystrophy Therapeutics Market Size by Application (2016-2027)
10.4 Middle East & Africa Duchenne Muscular Dystrophy Therapeutics Market Size by Country
10.4.1 Middle East & Africa Duchenne Muscular Dystrophy Therapeutics Market Size by Country (2016-2021)
10.4.2 Middle East & Africa Duchenne Muscular Dystrophy Therapeutics Market Size by Country (2022-2027)
10.4.3 Turkey
10.4.4 Saudi Arabia
10.4.5 UAE
11 Key Players Profiles
11.1 Bristol-Myers Squibb
11.1.1 Bristol-Myers Squibb Company Details
11.1.2 Bristol-Myers Squibb Business Overview
11.1.3 Bristol-Myers Squibb Duchenne Muscular Dystrophy Therapeutics Introduction
11.1.4 Bristol-Myers Squibb Revenue in Duchenne Muscular Dystrophy Therapeutics Business (2016-2021)
11.1.5 Bristol-Myers Squibb Recent Development
11.2 FibroGen (US)
11.2.1 FibroGen (US) Company Details
11.2.2 FibroGen (US) Business Overview
11.2.3 FibroGen (US) Duchenne Muscular Dystrophy Therapeutics Introduction
11.2.4 FibroGen (US) Revenue in Duchenne Muscular Dystrophy Therapeutics Business (2016-2021)
11.2.5 FibroGen (US) Recent Development
11.3 Italfarmaco (Italy)
11.3.1 Italfarmaco (Italy) Company Details
11.3.2 Italfarmaco (Italy) Business Overview
11.3.3 Italfarmaco (Italy) Duchenne Muscular Dystrophy Therapeutics Introduction
11.3.4 Italfarmaco (Italy) Revenue in Duchenne Muscular Dystrophy Therapeutics Business (2016-2021)
11.3.5 Italfarmaco (Italy) Recent Development
11.4 Marathon
11.4.1 Marathon Company Details
11.4.2 Marathon Business Overview
11.4.3 Marathon Duchenne Muscular Dystrophy Therapeutics Introduction
11.4.4 Marathon Revenue in Duchenne Muscular Dystrophy Therapeutics Business (2016-2021)
11.4.5 Marathon Recent Development
11.5 NS Pharma (US)
11.5.1 NS Pharma (US) Company Details
11.5.2 NS Pharma (US) Business Overview
11.5.3 NS Pharma (US) Duchenne Muscular Dystrophy Therapeutics Introduction
11.5.4 NS Pharma (US) Revenue in Duchenne Muscular Dystrophy Therapeutics Business (2016-2021)
11.5.5 NS Pharma (US) Recent Development
11.6 PTC Therapeutics (US)
11.6.1 PTC Therapeutics (US) Company Details
11.6.2 PTC Therapeutics (US) Business Overview
11.6.3 PTC Therapeutics (US) Duchenne Muscular Dystrophy Therapeutics Introduction
11.6.4 PTC Therapeutics (US) Revenue in Duchenne Muscular Dystrophy Therapeutics Business (2016-2021)
11.6.5 PTC Therapeutics (US) Recent Development
11.7 Pfizer
11.7.1 Pfizer Company Details
11.7.2 Pfizer Business Overview
11.7.3 Pfizer Duchenne Muscular Dystrophy Therapeutics Introduction
11.7.4 Pfizer Revenue in Duchenne Muscular Dystrophy Therapeutics Business (2016-2021)
11.7.5 Pfizer Recent Development
11.8 ReveraGen BioPharma (US)
11.8.1 ReveraGen BioPharma (US) Company Details
11.8.2 ReveraGen BioPharma (US) Business Overview
11.8.3 ReveraGen BioPharma (US) Duchenne Muscular Dystrophy Therapeutics Introduction
11.8.4 ReveraGen BioPharma (US) Revenue in Duchenne Muscular Dystrophy Therapeutics Business (2016-2021)
11.8.5 ReveraGen BioPharma (US) Recent Development
11.9 Santhera Pharmaceuticals (Switzerland)
11.9.1 Santhera Pharmaceuticals (Switzerland) Company Details
11.9.2 Santhera Pharmaceuticals (Switzerland) Business Overview
11.9.3 Santhera Pharmaceuticals (Switzerland) Duchenne Muscular Dystrophy Therapeutics Introduction
11.9.4 Santhera Pharmaceuticals (Switzerland) Revenue in Duchenne Muscular Dystrophy Therapeutics Business (2016-2021)
11.9.5 Santhera Pharmaceuticals (Switzerland) Recent Development
11.10 Sarepta Therapeutics (US)
11.10.1 Sarepta Therapeutics (US) Company Details
11.10.2 Sarepta Therapeutics (US) Business Overview
11.10.3 Sarepta Therapeutics (US) Duchenne Muscular Dystrophy Therapeutics Introduction
11.10.4 Sarepta Therapeutics (US) Revenue in Duchenne Muscular Dystrophy Therapeutics Business (2016-2021)
11.10.5 Sarepta Therapeutics (US) Recent Development
12 Analyst’s Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details
Table 1. Global Duchenne Muscular Dystrophy Therapeutics Market Size Growth Rate by Type (US$ Million):2016 VS 2021 VS 2027
Table 2. Key Players of Pain Management Drugs
Table 3. Key Players of Corticosteroids
Table 4. Key Players of Prednisolone
Table 5. Key Players of Prednisone
Table 6. Key Players of Deflazacort
Table 7. Global Duchenne Muscular Dystrophy Therapeutics Market Size Growth by Application (US$ Million): 2016 VS 2021 VS 2027
Table 8. Global Duchenne Muscular Dystrophy Therapeutics Market Size by Regions (US$ Million): 2016 VS 2021 VS 2027
Table 9. Global Duchenne Muscular Dystrophy Therapeutics Market Size by Regions (2016-2021) & (US$ Million)
Table 10. Global Duchenne Muscular Dystrophy Therapeutics Market Share by Regions (2016-2021)
Table 11. Global Duchenne Muscular Dystrophy Therapeutics Forecasted Market Size by Regions (2022-2027) & (US$ Million)
Table 12. Global Duchenne Muscular Dystrophy Therapeutics Market Share by Regions (2022-2027)
Table 13. Duchenne Muscular Dystrophy Therapeutics Market Trends
Table 14. Duchenne Muscular Dystrophy Therapeutics Market Drivers
Table 15. Duchenne Muscular Dystrophy Therapeutics Market Challenges
Table 16. Duchenne Muscular Dystrophy Therapeutics Market Restraints
Table 17. Global Duchenne Muscular Dystrophy Therapeutics Revenue by Players (2016-2021) & (US$ Million)
Table 18. Global Duchenne Muscular Dystrophy Therapeutics Market Share by Players (2016-2021)
Table 19. Global Top Duchenne Muscular Dystrophy Therapeutics Players by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Duchenne Muscular Dystrophy Therapeutics as of 2020)
Table 20. Ranking of Global Top Duchenne Muscular Dystrophy Therapeutics Companies by Revenue (US$ Million) in 2020
Table 21. Global 5 Largest Players Market Share by Duchenne Muscular Dystrophy Therapeutics Revenue (CR5 and HHI) & (2016-2021)
Table 22. Key Players Headquarters and Area Served
Table 23. Key Players Duchenne Muscular Dystrophy Therapeutics Product Solution and Service
Table 24. Date of Enter into Duchenne Muscular Dystrophy Therapeutics Market
Table 25. Mergers & Acquisitions, Expansion Plans
Table 26. Global Duchenne Muscular Dystrophy Therapeutics Market Size by Type (2016-2021) (US$ Million)
Table 27. Global Duchenne Muscular Dystrophy Therapeutics Revenue Market Share by Type (2016-2021)
Table 28. Global Duchenne Muscular Dystrophy Therapeutics Forecasted Market Size by Type (2022-2027) (US$ Million)
Table 29. Global Duchenne Muscular Dystrophy Therapeutics Revenue Market Share by Type (2022-2027) & (US$ Million)
Table 30. Global Duchenne Muscular Dystrophy Therapeutics Market Size Share by Application (2016-2021) & (US$ Million)
Table 31. Global Duchenne Muscular Dystrophy Therapeutics Revenue Market Share by Application (2016-2021)
Table 32. Global Duchenne Muscular Dystrophy Therapeutics Forecasted Market Size by Application (2022-2027) (US$ Million)
Table 33. Global Duchenne Muscular Dystrophy Therapeutics Revenue Market Share by Application (2022-2027) & (US$ Million)
Table 34. North America Duchenne Muscular Dystrophy Therapeutics Market Size by Type (2016-2021) (US$ Million)
Table 35. North America Duchenne Muscular Dystrophy Therapeutics Market Size by Type (2022-2027) & (US$ Million)
Table 36. North America Duchenne Muscular Dystrophy Therapeutics Market Size by Application (2016-2021) (US$ Million)
Table 37. North America Duchenne Muscular Dystrophy Therapeutics Market Size by Application (2022-2027) & (US$ Million)
Table 38. North America Duchenne Muscular Dystrophy Therapeutics Market Size by Country (2016-2021) & (US$ Million)
Table 39. North America Duchenne Muscular Dystrophy Therapeutics Market Size by Country (2022-2027) & (US$ Million)
Table 40. Europe Duchenne Muscular Dystrophy Therapeutics Market Size by Type (2016-2021) (US$ Million)
Table 41. Europe Duchenne Muscular Dystrophy Therapeutics Market Size by Type (2022-2027) & (US$ Million)
Table 42. Europe Duchenne Muscular Dystrophy Therapeutics Market Size by Application (2016-2021) (US$ Million)
Table 43. Europe Duchenne Muscular Dystrophy Therapeutics Market Size by Application (2022-2027) & (US$ Million)
Table 44. Europe Duchenne Muscular Dystrophy Therapeutics Market Size by Country (2016-2021) & (US$ Million)
Table 45. Europe Duchenne Muscular Dystrophy Therapeutics Market Size by Country (2022-2027) & (US$ Million)
Table 46. Asia-Pacific Duchenne Muscular Dystrophy Therapeutics Market Size by Type (2016-2021) (US$ Million)
Table 47. Asia-Pacific Duchenne Muscular Dystrophy Therapeutics Market Size by Type (2022-2027) & (US$ Million)
Table 48. Asia-Pacific Duchenne Muscular Dystrophy Therapeutics Market Size by Application (2016-2021) (US$ Million)
Table 49. Asia-Pacific Duchenne Muscular Dystrophy Therapeutics Market Size by Application (2022-2027) & (US$ Million)
Table 50. Asia-Pacific Duchenne Muscular Dystrophy Therapeutics Market Size by Region (2016-2021) & (US$ Million)
Table 51. Asia-Pacific Duchenne Muscular Dystrophy Therapeutics Market Size by Region (2022-2027) & (US$ Million)
Table 52. Latin America Duchenne Muscular Dystrophy Therapeutics Market Size by Type (2016-2021) (US$ Million)
Table 53. Latin America Duchenne Muscular Dystrophy Therapeutics Market Size by Type (2022-2027) & (US$ Million)
Table 54. Latin America Duchenne Muscular Dystrophy Therapeutics Market Size by Application (2016-2021) (US$ Million)
Table 55. Latin America Duchenne Muscular Dystrophy Therapeutics Market Size by Application (2022-2027) & (US$ Million)
Table 56. Latin America Duchenne Muscular Dystrophy Therapeutics Market Size by Country (2016-2021) & (US$ Million)
Table 57. Latin America Duchenne Muscular Dystrophy Therapeutics Market Size by Country (2022-2027) & (US$ Million)
Table 58. Middle East & Africa Duchenne Muscular Dystrophy Therapeutics Market Size by Type (2016-2021) (US$ Million)
Table 59. Middle East & Africa Duchenne Muscular Dystrophy Therapeutics Market Size by Type (2022-2027) & (US$ Million)
Table 60. Middle East & Africa Duchenne Muscular Dystrophy Therapeutics Market Size by Application (2016-2021) (US$ Million)
Table 61. Middle East & Africa Duchenne Muscular Dystrophy Therapeutics Market Size by Application (2022-2027) & (US$ Million)
Table 62. Middle East & Africa Duchenne Muscular Dystrophy Therapeutics Market Size by Country (2016-2021) & (US$ Million)
Table 63. Middle East & Africa Duchenne Muscular Dystrophy Therapeutics Market Size by Country (2022-2027) & (US$ Million)
Table 64. Bristol-Myers Squibb Company Details
Table 65. Bristol-Myers Squibb Business Overview
Table 66. Bristol-Myers Squibb Duchenne Muscular Dystrophy Therapeutics Product
Table 67. Bristol-Myers Squibb Revenue in Duchenne Muscular Dystrophy Therapeutics Business (2016-2021) & (US$ Million)
Table 68. Bristol-Myers Squibb Recent Development
Table 69. FibroGen (US) Company Details
Table 70. FibroGen (US) Business Overview
Table 71. FibroGen (US) Duchenne Muscular Dystrophy Therapeutics Product
Table 72. FibroGen (US) Revenue in Duchenne Muscular Dystrophy Therapeutics Business (2016-2021) & (US$ Million)
Table 73. FibroGen (US) Recent Development
Table 74. Italfarmaco (Italy) Company Details
Table 75. Italfarmaco (Italy) Business Overview
Table 76. Italfarmaco (Italy) Duchenne Muscular Dystrophy Therapeutics Product
Table 77. Italfarmaco (Italy) Revenue in Duchenne Muscular Dystrophy Therapeutics Business (2016-2021) & (US$ Million)
Table 78. Italfarmaco (Italy) Recent Development
Table 79. Marathon Company Details
Table 80. Marathon Business Overview
Table 81. Marathon Duchenne Muscular Dystrophy Therapeutics Product
Table 82. Marathon Revenue in Duchenne Muscular Dystrophy Therapeutics Business (2016-2021) & (US$ Million)
Table 83. Marathon Recent Development
Table 84. NS Pharma (US) Company Details
Table 85. NS Pharma (US) Business Overview
Table 86. NS Pharma (US) Duchenne Muscular Dystrophy Therapeutics Product
Table 87. NS Pharma (US) Revenue in Duchenne Muscular Dystrophy Therapeutics Business (2016-2021) & (US$ Million)
Table 88. NS Pharma (US) Recent Development
Table 89. PTC Therapeutics (US) Company Details
Table 90. PTC Therapeutics (US) Business Overview
Table 91. PTC Therapeutics (US) Duchenne Muscular Dystrophy Therapeutics Product
Table 92. PTC Therapeutics (US) Revenue in Duchenne Muscular Dystrophy Therapeutics Business (2016-2021) & (US$ Million)
Table 93. PTC Therapeutics (US) Recent Development
Table 94. Pfizer Company Details
Table 95. Pfizer Business Overview
Table 96. Pfizer Duchenne Muscular Dystrophy Therapeutics Product
Table 97. Pfizer Revenue in Duchenne Muscular Dystrophy Therapeutics Business (2016-2021) & (US$ Million)
Table 98. Pfizer Recent Development
Table 99. ReveraGen BioPharma (US) Company Details
Table 100. ReveraGen BioPharma (US) Business Overview
Table 101. ReveraGen BioPharma (US) Revenue in Duchenne Muscular Dystrophy Therapeutics Business (2016-2021) & (US$ Million)
Table 102. ReveraGen BioPharma (US) Recent Development
Table 103. Santhera Pharmaceuticals (Switzerland) Company Details
Table 104. Santhera Pharmaceuticals (Switzerland) Business Overview
Table 105. Santhera Pharmaceuticals (Switzerland) Duchenne Muscular Dystrophy Therapeutics Product
Table 106. Santhera Pharmaceuticals (Switzerland) Revenue in Duchenne Muscular Dystrophy Therapeutics Business (2016-2021) & (US$ Million)
Table 107. Santhera Pharmaceuticals (Switzerland) Recent Development
Table 108. Sarepta Therapeutics (US) Company Details
Table 109. Sarepta Therapeutics (US) Business Overview
Table 110. Sarepta Therapeutics (US) Duchenne Muscular Dystrophy Therapeutics Product
Table 111. Sarepta Therapeutics (US) Revenue in Duchenne Muscular Dystrophy Therapeutics Business (2016-2021) & (US$ Million)
Table 112. Sarepta Therapeutics (US) Recent Development
Table 113. Research Programs/Design for This Report
Table 114. Key Data Information from Secondary Sources
Table 115. Key Data Information from Primary Sources
List of Figures
Figure 1. Global Duchenne Muscular Dystrophy Therapeutics Market Share by Type: 2020 VS 2027
Figure 2. Pain Management Drugs Features
Figure 3. Corticosteroids Features
Figure 4. Prednisolone Features
Figure 5. Prednisone Features
Figure 6. Deflazacort Features
Figure 7. Global Duchenne Muscular Dystrophy Therapeutics Market Share by Application: 2020 VS 2027
Figure 8. Hospitals Case Studies
Figure 9. Clinics Case Studies
Figure 10. Home Care Settings Case Studies
Figure 11. Duchenne Muscular Dystrophy Therapeutics Report Years Considered
Figure 12. Global Duchenne Muscular Dystrophy Therapeutics Market Size (US$ Million), Year-over-Year: 2016-2027
Figure 13. Global Duchenne Muscular Dystrophy Therapeutics Market Size (US$ Million), 2016 VS 2021 VS 2027
Figure 14. Global Duchenne Muscular Dystrophy Therapeutics Market Share by Regions: 2020 VS 2027
Figure 15. Global Duchenne Muscular Dystrophy Therapeutics Market Share by Regions (2022-2027)
Figure 16. Global Duchenne Muscular Dystrophy Therapeutics Market Share by Players in 2020
Figure 17. Global Top Duchenne Muscular Dystrophy Therapeutics Players by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Duchenne Muscular Dystrophy Therapeutics as of 2020
Figure 18. The Top 10 and 5 Players Market Share by Duchenne Muscular Dystrophy Therapeutics Revenue in 2020
Figure 19. Global Duchenne Muscular Dystrophy Therapeutics Revenue Market Share by Type (2016-2021)
Figure 20. Global Duchenne Muscular Dystrophy Therapeutics Revenue Market Share by Type (2022-2027)
Figure 21. North America Duchenne Muscular Dystrophy Therapeutics Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 22. North America Duchenne Muscular Dystrophy Therapeutics Market Share by Type (2016-2027)
Figure 23. North America Duchenne Muscular Dystrophy Therapeutics Market Share by Application (2016-2027)
Figure 24. North America Duchenne Muscular Dystrophy Therapeutics Market Share by Country (2016-2027)
Figure 25. United States Duchenne Muscular Dystrophy Therapeutics Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 26. Canada Duchenne Muscular Dystrophy Therapeutics Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 27. Europe Duchenne Muscular Dystrophy Therapeutics Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 28. Europe Duchenne Muscular Dystrophy Therapeutics Market Share by Type (2016-2027)
Figure 29. Europe Duchenne Muscular Dystrophy Therapeutics Market Share by Application (2016-2027)
Figure 30. Europe Duchenne Muscular Dystrophy Therapeutics Market Share by Country (2016-2027)
Figure 31. Germany Duchenne Muscular Dystrophy Therapeutics Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 32. France Duchenne Muscular Dystrophy Therapeutics Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 33. U.K. Duchenne Muscular Dystrophy Therapeutics Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 34. Italy Duchenne Muscular Dystrophy Therapeutics Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 35. Russia Duchenne Muscular Dystrophy Therapeutics Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 36. Nordic Duchenne Muscular Dystrophy Therapeutics Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 37. Asia-Pacific Duchenne Muscular Dystrophy Therapeutics Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 38. Asia-Pacific Duchenne Muscular Dystrophy Therapeutics Market Share by Type (2016-2027)
Figure 39. Asia-Pacific Duchenne Muscular Dystrophy Therapeutics Market Share by Application (2016-2027)
Figure 40. Asia-Pacific Duchenne Muscular Dystrophy Therapeutics Market Share by Region (2016-2027)
Figure 41. China Duchenne Muscular Dystrophy Therapeutics Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 42. Japan Duchenne Muscular Dystrophy Therapeutics Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 43. South Korea Duchenne Muscular Dystrophy Therapeutics Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 44. Southeast Asia Duchenne Muscular Dystrophy Therapeutics Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 45. India Duchenne Muscular Dystrophy Therapeutics Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 46. Australia Duchenne Muscular Dystrophy Therapeutics Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 47. Latin America Duchenne Muscular Dystrophy Therapeutics Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 48. Latin America Duchenne Muscular Dystrophy Therapeutics Market Share by Type (2016-2027)
Figure 49. Latin America Duchenne Muscular Dystrophy Therapeutics Market Share by Application (2016-2027)
Figure 50. Latin America Duchenne Muscular Dystrophy Therapeutics Market Share by Country (2016-2027)
Figure 51. Mexico Duchenne Muscular Dystrophy Therapeutics Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 52. Brazil Duchenne Muscular Dystrophy Therapeutics Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 53. Middle East & Africa Duchenne Muscular Dystrophy Therapeutics Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 54. Middle East & Africa Duchenne Muscular Dystrophy Therapeutics Market Share by Type (2016-2027)
Figure 55. Middle East & Africa Duchenne Muscular Dystrophy Therapeutics Market Share by Application (2016-2027)
Figure 56. Middle East & Africa Duchenne Muscular Dystrophy Therapeutics Market Share by Country (2016-2027)
Figure 57. Turkey Duchenne Muscular Dystrophy Therapeutics Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 58. Saudi Arabia Duchenne Muscular Dystrophy Therapeutics Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 59. UAE Duchenne Muscular Dystrophy Therapeutics Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 60. Bristol-Myers Squibb Revenue Growth Rate in Duchenne Muscular Dystrophy Therapeutics Business (2016-2021)
Figure 61. FibroGen (US) Revenue Growth Rate in Duchenne Muscular Dystrophy Therapeutics Business (2016-2021)
Figure 62. Italfarmaco (Italy) Revenue Growth Rate in Duchenne Muscular Dystrophy Therapeutics Business (2016-2021)
Figure 63. Marathon Revenue Growth Rate in Duchenne Muscular Dystrophy Therapeutics Business (2016-2021)
Figure 64. NS Pharma (US) Revenue Growth Rate in Duchenne Muscular Dystrophy Therapeutics Business (2016-2021)
Figure 65. PTC Therapeutics (US) Revenue Growth Rate in Duchenne Muscular Dystrophy Therapeutics Business (2016-2021)
Figure 66. Pfizer Revenue Growth Rate in Duchenne Muscular Dystrophy Therapeutics Business (2016-2021)
Figure 67. ReveraGen BioPharma (US) Revenue Growth Rate in Duchenne Muscular Dystrophy Therapeutics Business (2016-2021)
Figure 68. Santhera Pharmaceuticals (Switzerland) Revenue Growth Rate in Duchenne Muscular Dystrophy Therapeutics Business (2016-2021)
Figure 69. Sarepta Therapeutics (US) Revenue Growth Rate in Duchenne Muscular Dystrophy Therapeutics Business (2016-2021)
Figure 70. Bottom-up and Top-down Approaches for This Report
Figure 71. Data Triangulation
Figure 72. Key Executives Interviewed